Shots:

• The US FDA has granted BTD to mavacamten for the treatment of symptomatic- obstructive hypertrophic cardiomyopathy (HCM)
• In May’2021- MyoKardia reported the results of the P-III EXPLORER study that demonstrated the robust treatment effect- with patient responses to treatment- including reductions in symptoms- improvements in cardiac function and reduction or elimination of the obstruction of the left ventricle and was well tolerated
• MyoKardia is currently preparing an NDA for mavacamten- with plans to submit to the FDA in Q1’21

 ­ Ref: GlobeNewswire | Image: MyoKardia